1. Home
  2. CTNM vs GLU Comparison

CTNM vs GLU Comparison

Compare CTNM & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • GLU
  • Stock Information
  • Founded
  • CTNM 2009
  • GLU 2004
  • Country
  • CTNM United States
  • GLU United States
  • Employees
  • CTNM N/A
  • GLU N/A
  • Industry
  • CTNM
  • GLU Finance/Investors Services
  • Sector
  • CTNM
  • GLU Finance
  • Exchange
  • CTNM Nasdaq
  • GLU Nasdaq
  • Market Cap
  • CTNM 122.9M
  • GLU 99.4M
  • IPO Year
  • CTNM 2024
  • GLU N/A
  • Fundamental
  • Price
  • CTNM $3.84
  • GLU $17.43
  • Analyst Decision
  • CTNM Strong Buy
  • GLU
  • Analyst Count
  • CTNM 4
  • GLU 0
  • Target Price
  • CTNM $22.50
  • GLU N/A
  • AVG Volume (30 Days)
  • CTNM 222.5K
  • GLU 12.4K
  • Earning Date
  • CTNM 08-12-2025
  • GLU 01-01-0001
  • Dividend Yield
  • CTNM N/A
  • GLU 8.60%
  • EPS Growth
  • CTNM N/A
  • GLU N/A
  • EPS
  • CTNM N/A
  • GLU 0.62
  • Revenue
  • CTNM N/A
  • GLU N/A
  • Revenue This Year
  • CTNM N/A
  • GLU N/A
  • Revenue Next Year
  • CTNM N/A
  • GLU N/A
  • P/E Ratio
  • CTNM N/A
  • GLU $22.50
  • Revenue Growth
  • CTNM N/A
  • GLU N/A
  • 52 Week Low
  • CTNM $3.35
  • GLU $11.61
  • 52 Week High
  • CTNM $22.00
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • GLU 68.03
  • Support Level
  • CTNM N/A
  • GLU $16.98
  • Resistance Level
  • CTNM N/A
  • GLU $17.35
  • Average True Range (ATR)
  • CTNM 0.00
  • GLU 0.20
  • MACD
  • CTNM 0.00
  • GLU 0.04
  • Stochastic Oscillator
  • CTNM 0.00
  • GLU 100.00

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: